Clinical trial
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
NCT07906145 is registered in ClinicalTrials.gov with Shanghai Qilu Pharmaceutical Research and Development Center LTD as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, Phase 1, 76 participants (estimated). Lead sponsor Shanghai Qilu Pharmaceutical Research and Development Center LTD. Primary measure: Safety and Tolerability of QLS2416 Injection.
How it compares
39 similar trials: same condition (Sjogren's Syndrome) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
- Official title
- A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of QLS2416 Injection in Participants With Autoimmune Diseases
- Lead sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- December 31, 2029
- Enrollment
- 76 (estimated)
- Sites
- Not reported
Conditions
MeSH condition names; the registry's own terms follow.
Arthritis, Rheumatoid, Autoimmune Diseases, Lupus Erythematosus, Systemic, Scleroderma, Systemic, Sjogren's Syndrome
Registry terms: primary sjögren's syndrome (pss), rheumatoid arthritis (ra), systemic lupus erythematosus, systemic sclerosis (ssc)
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| QLS2416 | Experimental | QLS2416 Injection |
Show registry wordingDose Escalation Part: Participants with active SLE, RA, or pSS will receive single ascending subcutaneous doses of QLS2416 injection across 7 dose levels (0.025 mg to 6.0 mg). Dose Expansion Part: Participants with active SLE or SSc will receive multiple dosing of QLS2416 injection at 3 dose levels within the 4-week treatment period. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Safety and Tolerability of QLS2416 Injection | Up to 24 weeks |
Show registry wordingIncidence and severity of treatment-emergent adverse events. | |
Lead sponsor's other trials
Shanghai Qilu Pharmaceutical Research and Development Center LTD, most recent start first.
+1 more trial
Similar trials
Same condition (Sjogren's Syndrome) and phase, most recent start first.
+34 more trials See the condition page